The study highlighted that mutations did not significantly affect PFS or overall survival in metastatic BC patients, suggesting that multi-gene panel testing should be considered for all metastatic BC patients due to the high mutation frequency, but also that the clinical utility of finding alterations in genes other than BRCA 1/2 (with the potential exception of PALB2) may be limited. The gene discussed is PALB2; the disease is breast cancer.